Evidence map›Paper›PMID 42218125›Full record

ArticleNature communications2026

Mitochondrial RNA degradation regulates differentiation, stemness, and immune sensitivity in acute myeloid leukemia.

Geethu Emily Thomas, Veronique Voisin, Kazem Nouri, Rose Hurren, Karen Kai-Lin Fang, Ali Chegini, Marcela Gronda, Yongran Yan, Neil MacLean, Yulia Jitkova and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Geethu Emily ThomasPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Veronique VoisinPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Kazem NouriPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Rose HurrenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Karen Kai-Lin FangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Ali CheginiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0009-0007-8249-7258
Marcela GrondaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Yongran YanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID http://orcid.org/0009-0005-7337-4331
Neil MacLeanPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Yulia JitkovaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Dakai LingPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Mary MaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Xiao Ming WangPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Andrea ArrudaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Vito SpadavecchioInterlinked Therapeutics LLC, Portland, OR, USA.
Mark D MindenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Li ZhangToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Jong Bok LeeToronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Aaron D SchimmerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. aaron.schimmer@uhn.ca.ORCID http://orcid.org/0000-0003-4023-3899

Funding

Gouvernement du Canada | Canadian Institutes of Health Research (Instituts de Recherche en Santé du Canada) FDN-154282
6 · The paper itself

Abstract

Eukaryotic cells have separate genomes in the nucleus and mitochondria. Mitochondrial DNA is transcribed bi-directionally to generate mitochondrial RNA (mtRNA) and dsRNA as a by-product of this transcription. We demonstrate that mtRNA transcription and degradation are increased in AML (Acute Myeloid Leukemia) cells and stem cells resulting in higher rates of mtRNA turnover. We discover that the mitochondrial degradosome, SUV3 and PNPase, is upregulated in AML cells and stem cells and functionally important for degradation of mtRNA and mitochondrial dsRNA (double stranded RNA) in AML. Depleting SUV3 or PNPase impairs mtRNA degradation and promotes the accumulation of dsRNA. dsRNA that accumulates after depleting SUV3 or PNPase, stimulates IFN-I signaling that induces AML differentiation, decreases stemness and increases sensitivity to immune-mediating cytotoxicity. Thus, this work highlights mitochondrial RNA regulation in AML and identifies a mechanism by which mtRNA turnover influences AML differentiation, stem cell function, and immune sensitization.

Indexed as

Cell DifferentiationLeukemia, Myeloid, AcuteNeoplastic Stem CellsRNA, MitochondrialRNA StabilityAnimalsCell Line, TumorDEAD-box RNA HelicasesEndoribonucleasesHumansMitochondriaPolyribonucleotide NucleotidyltransferaseRNA, Double-StrandedRNA HelicasesDEAD-box RNA HelicasesEndoribonucleasesPolyribonucleotide NucleotidyltransferaseRNA, Double-StrandedRNA HelicasesRNA, MitochondrialSUPV3L1 protein, human

Identifiers

PMID42218125
PMCPMC13396181

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.